MAP - Market Access Podcast

By Dr. Stefan WalzerBusiness Science Medicine Health & Fitness

MAP - Market Access Podcast episodes

July 15, 2025 What Does It Really Take to Master AMNOG in Today’s Market Access Landscape, Anja Pownell?
Tune in to this new episode of the Market Access Podcast, where our host Dr. Stefan Walzer is joined by AMNOG expert Anja Pownell to bust some of the most persistent misconceptions about German market access—and share actionable survival tips for navigating the GBA process.
Learn how to strategically prepare for AMNOG submissions, navigate price negotiations, and leverage AI tools to streamline dossier writing and literature reviews. A must-listen for anyone involved in pharmaceutical pricing, reimbursement, and European market access strategy.
Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/
#MarketAccess #HealthEconomics #HealthcareInnovation #PharmaStrategy #AMNOG #PharmaInnovation #GBA #Reimbursement #marketaccess #marketaccesspodcast
26 min
July 01, 2025 Is Cross-Functional Alignment the Secret to Successful Market Access, Kasem Akhras?
In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with Kasem Akhras, veteran access strategist and author of Frontiers in Market Access, to unpack what it really takes to bring innovative therapies to patients across emerging markets. From the rising demand for innovative therapies to the tightening grip of healthcare budgets, this episode explores the real challenges and opportunities in market access today.
Discover why pricing strategies must be tailored to each market, how cross-functional collaboration and early planning are key to success, and how digital health and AI are reshaping the future of market access. A must-listen for anyone navigating the complexities of global market access.
Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/
#MarketAccess #HealthEconomics #EmergingMarkets #PricingStrategy #PharmaInnovation #DigitalHealth #AIinPharma #marketaccess #marketaccesspodcast
39 min
June 15, 2025 How Do You Unlock the Power of Statistics in Market Access, Necdet Gunsoy?
Tune in to the latest episode of the Market Access Podcast, where Dr. Stefan Walzer welcomes statistician and Evimed founder Necdet Gunsoy to explore the critical role of statistics in health economics, HTA, and payer strategy. Learn how better collaboration between statisticians and market access teams can drive evidence-based decision-making, improve communication, and support strategic planning—plus the impact of AI on future workflows.
This conversation spans key topics—from real-world evidence and health technology assessment (HTA) to internal cross-functional alignment and strategic planning in market access. Whether you're a health economist, market access leader, or data expert, this is a must-listen to improve cross-functional impact and efficiency.
Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/
#MarketAccess #HealthEconomics #HTA #Pharma #PayerStrategy #marketaccess #marketaccesspodcast
37 min
June 01, 2025 How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes? (Repost)
This is a repost of a popular episode of MAP - Market Access Podcast, from July 15th 2024.
Unlock the Future of Market Access with AI and Systematic Literature Reviews! Join Dr. Stefan Walzer in the latest episode of the Market Access Podcast as he delves into the transformative power of AI in systematic literature searches. Featuring Jeffrey Johnson and Kevin Kallmes from Nested Knowledge, this episode explores how their innovative platform revolutionizes literature reviews, making them faster, more efficient, and more enjoyable.
This episode is for anyone who wants to learn more about the integration of AI in market access, reimbursement planning, and dossier creation. Tune in to find out how AI is not only saving time but also enhancing the quality of research and market access strategies. Don’t miss this insightful discussion on the future of AI in healthcare!
Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/
#MarketAccess #AI #SystematicReview #HealthcareInnovation #Pharma #marketaccess #marketaccesspodcast
35 min
May 15, 2025 How Can Market Access Professionals Plan for Long-Term Success, Adrian Kielhorn?
What does it take to succeed in Market Access? In this brand new episode of MAP, the Market Access podcast, Dr. Stefan Walzer sits down with industry veteran Adrian Kielhorn, co-author of The Market Access Guide. Together, they unpack the evolving role of market access professionals, the power of strategic thinking, mastering negotiations, and why patient centricity is key to success.
Learn how to develop a strong value story, navigate pricing and reimbursement, and stay ahead in the dynamic pharmaceutical and healthcare landscape. Whether you’re a seasoned professional or just starting out, this episode is packed with insights, strategy, and a touch of humor to help you navigate the ever-changing market access landscape. Tune in now for expert insights on the future of market access & health economics!
Want to get ahold of The Market Access Guide? Get your copy here or download the Kindle version now!
Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/
#MarketAccess #Pharma #HealthEconomics #PatientCentricity #NegotiationSkills #PricingStrategy #PharmaceuticalIndustry #HealthcareInnovation #marketaccess #marketaccesspodcast
39 min
May 01, 2025 What Are the Biggest Challenges & Opportunities of JCA, Dr. Nick Leach?
In this brand new episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer is joined by Dr. Nick Leach, Market Access expert and managing director at Red Thread, to break down the Joint Clinical Assessment (JCA) process, its impact on pharma, biotech, and medical device companies, and how early advice can shape market access and reimbursement strategies in Europe.
Tune in to learn about JCA’s mandatory requirements, challenges, opportunities, and future developments as companies prepare for the evolving EU market access framework. JCA is changing the market access landscape in Europe - don’t miss out on this insightful discussion!
Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/
#MarketAccess #JCA #Pharma #HealthEconomics #HTA #Reimbursement #Biotech #marketaccess #marketaccesspodcast
36 min
April 15, 2025 Are We Overlooking the Real Benefits of Medical Innovation, Dr. Ahmed Seddik?
Join the latest episode of the Market Access Podcast, where our host Dr. Stefan Walzer and expert Dr. Ahmed Seddik dissect the complexities of the societal impact of medical innovation. Dr. Ahmed Seddik shares important insights from his journey starting as a dentist in Egypt to his PhD research in health economics and social impact, focusing on how the access to innovation transforms communities and economies.
Explore how medical innovation shapes healthcare systems and economies, and take part in the discussion of how health economics, cost-effectiveness, and societal impact influence reimbursement decisions. Listen now to learn more about how different countries integrate social value into healthcare policies and what the future holds for market access and innovation adoption.
Curious to explore this topic further? You can find Ahmed Seddik’s thesis here: The social impact of medical innovations
Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/
#MarketAccess #HealthEconomics #MedicalInnovation #SocialImpact #HealthcarePolicy #marketaccess #marketaccesspodcast
34 min
April 01, 2025 What Are the Biggest Challenges in Implementing AI in Pharma, Jan Kroschinski?
How can AI revolutionize Market Access, and what does it take to drive successful change in pharma? Tune into the latest episode of MAP, the Market Access Podcast, where our host Dr. Stefan Walzer and Jan Kroschinski, an expert in digital transformation, will delve into change management and AI adoption in pharma.
Follow along as they explore how AI can streamline processes like dossier writing and HTA submissions, while tackling resistance to change. Discover strategies for effective AI adoption, leadership engagement, and risk vs. opportunity - how to shift from fear-based thinking to opportunity-driven AI adoption. Get ahead of the AI curve with this insightful discussion!
Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/
#MarketAccess #AI #DigitalTransformation #ChangeManagement #Pharma #HealthTech #marketaccess #marketaccesspodcast
44 min
March 15, 2025 How Can Startups Leverage Market Access to Attract Investors, Johan Olsson?
In the latest episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer sits down with Johan Olsson, a seasoned life sciences investor, to uncover the critical role of market access and reimbursement in early-stage healthcare investments.
They explore how early market access planning impacts healthcare startups, investment decisions, and commercialization success. Discover why pricing, reimbursement, and payer strategies are key to securing funding, mitigating risk, and maximizing valuation. An understanding of the market access landscape can make or break a healthcare startup’s valuation, funding potential, and commercial viability. Tune in now to learn how to navigate market access for healthcare investments!
Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/
#MarketAccess #HealthcareInvestments #BiotechStartups #ReimbursementStrategies #Commercialization #AIHealthcare #marketaccess #marketaccesspodcast
34 min
March 01, 2025 How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali?
In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data privacy challenges, delays in commercialization, and the future of healthcare data regulation.
Learn more about how data privacy laws create barriers for cross-border studies, delaying access to life-saving treatments, and how companies can navigate these hurdles and optimize market entry strategies. Can Europe find a balance between data privacy and innovation? Tune in to explore the challenges, solutions, and what’s next for healthcare in the EU.
Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/
#GDPR, #MarketAccess, #Real-WorldEvidence, #HealthcareData, #Pharma, #MedTech, #Cross-BorderStudies #marketaccess #marketaccesspodcast
35 min

About MAP - Market Access Podcast

From the publisher's feed

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.

MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.

The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.

Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).

Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.

Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.